Tag: Leuprorelin

22. December 2022

Further EU Marketing Authorizations for AMW’s Leuprorelin Implant for the Treatment of Hormone-Sensitive Tumors

AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that the leuprorelin implant it developed has received additional marketing approvals in two European Union countries. Leuprorelin enables symptomatic therapy of hormone-sensitive tumors, such as prostate cancer, and of certain gynecological diseases. AMW’s leuprorelin implant is now approved as a cost-effective therapy in over ten countries worldwide.

25. October 2022

AMW and Mistral sign License and Supply Agreement for Commercialization of AMW’s Goserelin and Leuprorelin implants

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, and Mistral Capital Management Ltd, a pharmaceutical company specialized in distribution and promotion of high-quality medicines, today announced that they have entered into a semi-exclusive license and supply agreement (LSA) for the commercialization of AMW’s goserelin and leuprorelin implants in two countries, including Ukraine.

19. October 2021

AMW signs license and supply agreements for the commercialization of its goserelin and leuprorelin implants in Israel

AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, announced today that license and supply agreements (LSAs) have been signed with an undisclosed partner for the commercialization of its goserelin and leuprorelin implants in Israel.

2. November 2020

Expansion of the partnership between AMW and Zentiva for Western Europe

Zentiva will include the leuprorelin implant to its portfolio for selected markets in Western Europe. This implant is another successful product of AMW, developed and produced by AMW The leuprorelin implant for the treatment of prostate cancer received its first marketing authorisation in Germany in 2018 and gained market share quickly.